Osteosarcoma is not an exception: MDM2 levels are increased in the low-grade, low-differentiated forms of the malignancy, and have been proposed to be used as a marker to identify the more aggressive subgroups [12]. This evidence concerns the gene MDM2 and osteosarcoma.